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Abstract
Background: We aimed to compare intra- and extracranial responses to immune checkpoint inhibitors (ICIs) in
lung cancer with brain metastases (BM), and to explore tumor microenvironments of the brain and lungs focusing
on the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway.
Methods: Two cohorts of lung cancer patients with BM were analyzed. Cohort 1 included 18 patients treated with
nivolumab or pembrolizumab, and intra- and extracranial responses were assessed. Cohort 2 comprised 20 patients
who underwent both primary lung surgery and brain metastasectomy. Specimens from cohort 2 were subjected to
immunohistochemical analysis for the following markers: CD3, CD4, CD8, FOXP3, and PD-1 on tumor infiltrating
lymphocytes (TIL) and PD-L1 on tumor cells.
Results: Seven patients (38.9%) in cohort 1 showed progressive disease in both primary and intracranial lesions.
Although the other 11 patients exhibited a partial response or stable disease in the primary lesion, eight showed a
progression in BM. Interestingly, PD-1+ TILs were significantly decreased in BM (P = 0.034). For fifteen patients with
adenocarcinoma, more distinctive patterns were observed in CD3+ (P = 0.078), CD8+ (P = 0.055), FOXP3+ (P = 0.016),
and PD-1+ (P = 0.016) TILs.
Conclusions: There may be discordant responses to an ICI of lung cancer between primary lung lesion and BM
based on discrepancies in the tumor microenvironment. The diminished infiltration of PD-1+ TILs in tumor tissue
within the brain may be one of the major factors that hinder the response to anti–PD-1 antibody in BM.
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Background
About 30% of advanced lung cancer patients develop brain
metastases (BM), and their prognosis as well as quality of
life are generally poor [1, 2]. The standard management for
these patients includes metastasectomy and radiotherapy—
either stereotactic radiosurgery or whole brain radiotherapy
(WBRT). However, despite an improved local control rate
[3], such localized treatments have inevitable toxic effects,
including cognitive decline or a deterioration in the pa-
tient’s quality of life [4–6]. Furthermore, local treatment
can delay the initiation of systemic treatment, which is cru-
cial in patients with rapidly progressive disease [7, 8]. Ac-
cordingly, systemic treatment is recommended for patients
with BM who are asymptomatic or experience only min-
imal neurological symptoms; this may provide a benefit for
BM while simultaneously treating extracranial disease [9].
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Recently, immune checkpoint inhibitors (ICIs) have
emerged as a promising new treatment in various cancer
types. These drugs, including anti–cytotoxic T-lymphocyte
antigen 4 (CTLA-4) antibodies and anti–programmed cell
death-1 (anti-PD-1)/programmed cell death ligand-1
(PD-L1) antibodies, reactivate the anti-tumor immunity of
T cells [10, 11]. Although the efficacy as a first-line
treatment in metastatic non-small-cell lung cancer
(NSCLC) was not evident yet, [12] nivolumab have
been approved by the US Food and Drug Administra-
tion (FDA) for the treatment of metastatic NSCLC
and has become standard treatment in a second-line
setting. [13–17]. However, most of these trials have
excluded patients with any history of BM or active/
symptomatic BM requiring steroid treatment. Further-
more, the evidence for immune checkpoint inhibitors in
the management of BM has been largely limited to retro-
spective analyses of melanoma metastases and ipilimumab
[18]. Therefore, the intracranial efficacy of ICIs is relatively
unknown and has not yet been validated.
In this regard, prospective clinical trials of ICIs are
currently under way, and tentative results suggested
activity [18]. Recent early phase clinical trials have
conducted to investigate the therapeutic efficacy of ICIs
on BM in patients with NSCLC or melanoma [19, 20].
Although they reported that pembrolizumab and ipili-
mumab can have therapeutic activity on BM in patients
with NSCLC and melanoma, many patients did not
showed response in the brain or in extracranial sites.
Further more, because these studies mainly included
patients without neurological symptoms or the need for
corticosteroids, the efficacy of ICIs on BM in real world
are still inconclusive yet. Additional studies addressing
combination treatment strategies and biomarker devel-
opment are necessarily warranted.
Over the past decade, the tumor microenvironment
(TME) has emerged as a critical regulator determining the
response of ICIs [21]. Because of the distinctive compos-
ition of the extracellular matrix (ECM) as well as im-
munological environments in the brain, the TME of the
brain has unique features that distinguishes it from the
TME in primary lung cancer [22]. For example, unusual
tissue-resident cell types, including microglia, astrocytes
and neurons, are present in the brain’s TME [23], Further-
more, more importantly, the brain is one of the immune
privileged organs that must be sheltered from im-
mune cell entry and/or attack. Therefore, the TME of
an early-stage brain tumor is generally immunosup-
pressive with essentially no trafficking or patrolling by per-
ipheral immune cells [23]. Because immuno-oncology
strategies rely on the sophisticated interaction between
the tumor and its microenvironment, such a peculiar
immunological environment of the brain presents a
formidable challenge to overcome.
In the era of immunotherapy, understanding how BM
are influenced by the immunological peculiarities of the
brain will be crucial to forging therapeutic advances in
lung cancer. The purposes of this study are 1) to com-
pare intracranial and extracranial responses to ICIs in
lung cancer patients with BM, and 2) to investigate dif-
ferences in the TME between lung and brain metastases,
focusing on the PD-1/PD-L1 pathway.
Methods
Patients and samples
Two independent cohorts of lung cancer patients were
retrospectively analyzed to investigate the differences be-
tween primary tumors and BM in two respects: cohort 1
for comparing extra/intracranial responses to anti–PD-1
antibody; cohort 2 for comparing differences in the im-
munological TME. Cohort 1 included advanced lung can-
cer patients who were treated with intravenous nivolumab
or pembrolizumab as part of an expanded access program
(EAP), Keynote 010 trial (NCT01905657), or in routine
practice from February 2014 to November 2016 at Seoul
National University Hospital (SNUH) and Seoul National
University Bundang Hospital. Treatment continued until
disease progression, unacceptable toxicity that precluded
continuing drug treatment, or death. Patients were allowed
to continue treatment despite disease progression if they
were deriving a clinical benefit according to an investiga-
tor’s assessment. Patients were eligible for treatment if they
had at least one BM, with the longest diameter being ≥5
mm, before or during treatment with anti–PD-1 antibody.
Patients who received local treatment for previously known
BM were not excluded. Cohort 2 included lung cancer pa-
tients who underwent both brain metastasectomies for
their BM, and primary lung surgery. Therefore, patients
who were available for paired lung cancer and BM surgical
specimens were enrolled. The Tissue Registry at SNUH
was searched between June 2011 and November 2016. Two
expert pathologists (S.H.K. and Y.K.J) reviewed tissue
sections for adequacy. This study was approved by the
SNUH Institutional Review Board (IRB approval number:
H-1702-158-836) and was conducted in accordance with
Declaration of Helsinki provisions.
Response evaluation
A systemic response to anti–PD-1 antibody was mea-
sured by standard Response Evaluation Criteria in
Solid Tumors (RECIST; version 1.1). An intracranial
response was assessed by brain gadolinium-enhanced
magnetic resonance imaging (MRI), using RECIST
modified to allow target central nerve system lesions,
5 mm or larger in maximum diameter, and with up to
five BMs permitted (modified RECIST) [24]. Repre-
sentative MRI images for response evaluations are
available in Additional file 1: Figure S1.
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Immunohistochemistry
Formalin-fixed paraffin-embedded specimens were exam-
ined by immuno-staining tumor cells and TILs. Immuno-
histochemistry (IHC) was performed using the following
antibodies: rabbit anti–PD-L1 (E1L3N) XP® mAb (Cell
Signaling Technology, Danvers, MA, USA), mouse
anti-CD3 mAb (DAKO, Santa Clara, CA, USA), mouse
anti-CD4 mAb (Cell Marque, Rocklin, CA, USA), rabbit
anti-CD8 mAb (Thermo Scientific Fischer, Rockford, IL,
USA), mouse anti–PD-1 mAb (Cell Marque, Rocklin, CA,
USA) and mouse anti-FOXP3 mAb (Abcam, Cambridge,
UK). IHC for TILs, except for CD8+ TILs, was performed
using a Benchmark XT autostainer (Ventana Medical
Systems, Basel, Switzerland). In the case of CD8+ IHC, a
Bond-Max automated immunostainer (Leica Microsys-
tems, Melbourne, Australia) was used. PD-L1 IHC was
evaluated based on the intensity and proportion of mem-
branous staining, with or without cytoplasmic staining, in
tumor cells and was scored as follows: 0+ (no appreciable
staining above background), 1+ (weak membranous stain-
ing and/or cytoplasmic staining), 2+ (moderate membran-
ous staining and/or cytoplasmic staining), and 3+ (strong
membranous staining and/or cytoplasmic staining) [25].
Each score was multiplied by the percentage of cells (0–
100%) to achieve a H-score; H-score = (% of cells 3+)×3 +
(% of cells 2+)×2 + (% of cells 1+). All slides were blinded
with respect to clinical characteristics and outcomes, and
were reviewed and scored by two experienced pathologists
(S.H.K. and, Y.K.J.).
Automated enumeration of tumor-infiltrating
lymphocytes
To determine the amount of CD3+, CD4+, CD8+, PD-1+
and FOXP3+ TILs, representative slides were immuno-
stained for CD3, CD4, CD8, PD-1 and FOXP3 and scanned
for virtual microscopy using an Aperio ScanScope (Aperio
Technologies, Vista, CA, USA). The number of TILs was
automatically counted in intact tumor areas lacking
necrosis using modified nuclear IHC algorithms in Aperio
ImageScope software, as previously described [25]. The
mean value of TILs per unit area (mm2) was calculated.
Statistical analysis
Extra- and intracranial responses to anti–PD-1 antibody
were descriptively analyzed. Differences in IHC markers
between primary and BM were assessed using the paired
Wilcoxon rank-sum test. Correlations between IHC
markers were evaluated by Spearman’s rank correlation
analysis. Survival analyses were performed for cohort 2
using the Kaplan–Meier method and were compared
using a log-rank test. Overall survival (OS) was mea-
sured from the date of brain metastasectomy until either
death due to any cause or the last follow-up date. A Cox
proportional hazard regression model was applied to
determine the hazard ratio (HR) for specific variables
with respect to OS. For all statistical analyses, two-sided
P-values < 0.05 were considered statistically significant.
All statistical analyses were carried out using R version
3.3.2 (http://www.r-project.org).
Results
Demographics of study subjects
The clinicodemographic characteristics of patients in the
two study cohorts are summarized in Table 1. Cohort 1
included 18 lung cancer patients who had BM before or
during anti–PD-1 treatment. Most patients had an
adenocarcinoma histology (66.7%), and stages IIIA–IV
disease (83.3%). Three patients (16.7%) received cerebral
irradiation by WBRT during treatment with an ICI. Co-
hort 2 included 20 lung cancer patients who underwent
brain metastasectomy, and therefore paired primary and
BM specimens were available. Seven pairs (35.0%) were
obtained from cases with synchronous disease at their
initial diagnosis, and 13 pairs (65.0%) were obtained
from patients with metachronous disease who under-
went metastasectomy 5 or more months after the initial
diagnosis. The median interval between acquisitions of
paired lesions was 17 months (range 0–81months). No
patient had been exposed to anti–PD-1 antibody in co-
hort 2, and five patients (25.0%) underwent cerebral ir-
radiation before the acquisition of specimens.
Analysis of cohort 1: Comparison of response to anti–PD-
1 antibody between primary lung cancer and brain
metastasis
Of 18 patients in cohort 1, the primary lung lesion had
progressed in seven patients (38.9%). All such patients
showed progressive disease in intracranial lesions (Fig. 1).
The primary lesion showed a stable disease (n = 9,
50.0%) and partial response (n = 2, 11.1%) in 11 patients,
with eight of these exhibiting progressive disease in BM.
Although two patients showed a partial response in
brain tumors, they were found to have received WBRT
with nivolumab. Collectively, these results implied that
BM was poorly responsive to anti–PD-1 antibody com-
pared with the primary lung lesion.
Analysis of cohort 2: Comparison of immunological tumor
microenvironment between primary lung cancer and
brain metastasis
On the hypothesis that the distinctive immunological
TME of the brain determines the response to the
anti–PD-1 antibody, the amounts of TILs and PD-L1
expression on tumor cells in the brain TME were
compared with those of primary lung cancer speci-
mens (Fig. 2). Only twelve (60.0%) out of 20 patients
in cohort 2 were eligible for a paired comparison be-
cause lung biopsy specimens obtained from the other
Kim et al. BMC Cancer           (2019) 19:19 Page 3 of 10
Table 1 Clinicodemographic characteristics of patients in cohorts 1 and 2. Cohort 1 consisted of 18 lung cancer patients who
underwent brain metastasectomy for metastatic brain tumors, while cohort 2 included 20 lung cancer patients with brain
metastases who were treated with anti–PD-1 antibody (nivolumab or pembrolizumab). The two patient cohorts were independent
of each other
Characteristics Cohort 1 (N = 18) Cohort 2 (N = 20)
Age, median (range) 59 (32–76) 60 (33–77)
Sex, n (%)
Male 12 (66.7) 10 (50)
Female 6 (33.3) 10 (50)
Smoking, n (%)
Current smoker 4 (22.2) 7 (35.0)
Ex-smoker 6 (33.3) 3 (15.0)
Never smoked 8 (44.4) 10 (50.0)
Stage at diagnosisa), n (%)
IA–IIB 1 (5.6) 4 (20.0)
IIIA–IV 15 (83.3) 16 (80.0)
Extensive disease (for small cell lung cancer) 2 (11.1) 0 (0.0)
Histology, n (%)
Adenocarcinoma 12 (66.7) 15 (75.0)
Squamous cell carcinoma 1 (5.6) 4 (20.0)
Sarcomatoid carcinoma 2 (11.1) 1 (5.0)
Small cell lung cancer 2 (11.1) 0 (0.0)
Mutational status, n (%)
EGFR 3 (16.7) 9 (45.0)
ALK 2 (11.1) 0 (0.0)
Temporal relationship, n (%)
Synchronous NA 7 (35.0)
Metachronous NA 13 (65.0)
Anti–PD-1 antibody treatment
Nivolumab 14 (77.8) NA
Pembrolizumab 4 (22.2) NA
No. of chemotherapy treatments before EAP or brain surgery, n (%)
0 0 (0.0) 8 (40.0)
1 6 (33.3) 7 (35.0)
2 7 (38.9) 2 (10.0)
≥ 3 5 (27.8) 3 (15.0)
Cerebral irradiation before EAP or brain surgery, n (%)
Whole brain radiotherapy 3 (16.7) 2 (10.0)
Radiosurgery 4 (22.2) 2 (10.0)
Both 3 (16.7) 1 (5.0)
Cerebral irradiation during EAP, n (%)
Whole brain radiotherapy 3 (16.7) NA
Radiosurgery 0 (0.0) NA
Both 0 (0.0) NA
aTNM classification according to the 7th edition of the AJCC cancer staging manual
Abbreviations: EGFR Epidermal growth factor receptor, ALK anaplastic lymphoma kinase, PD-1 programmed cell death-1, AJCC American Joint Committee on
Cancer, EAP expanded access program
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eight patients were too small to evaluate the TME;
Three of them had synchronous BM, while the others
had metachronous BM. The median interval between
acquisitions of paired lesions in patients metachronous
BM was 23.4 months (range 4.7–81.5 months). The
eight patients were not excluded from cohort 2 because
they were eligible for survival analysis. The amounts of
CD3+, CD4+, and CD8+ TILs, and the PD-L1 H-score
of tumor cells did not show statistically significant dif-
ferences between primary lung cancers and BM tissues,
with P values of 0.148, 0.123, 0.622 and 0.675, respect-
ively. On the other hand, FOXP3+ TILs showed a de-
creasing tendency in the intracranial lesion (P = 0.077),
and, more interestingly, PD-1+ TILs decreased in the
brain in a statistically significant manner (P = 0.034).
For fifteen patients with adenocarcinoma (75.0%), more
distinctive patterns were observed in CD3+ (P = 0.078),
CD8+ (P = 0.055), FOXP+ (P = 0.016), and PD1+ (P =
0.016) TILs (Additional file 2: Figure S2). Figure 3
shows representative images of a male patient (ID 17 of
cohort 2) with adenocarcinoma histology. In the BM
specimen of the patient, PD-1+ and CD8+ TILs were
dramatically decreased, while PD-L1 expression on
tumor cells was relatively unchanged. The infiltration
of CD3+ TILs correlated positively with the PD-L1
H-score of tumor cells in the primary lung cancer
(Spearman ρ = 0.545, P = 0.083; Additional file 3: Figure
S3A), and BM (Spearman ρ = 0.444, P = 0.049; Add-
itional file 3: Figure S3B). No correlation between PD1
+ TILs and PD-L1 expression was noted in the primary
lung cancer Spearman ρ = 0.116, P = 0.720; Additional
file 3: Figure S3C). In contrast, the infiltration of PD1+
TILs positively correlated with PD-L1 expression of
tumor cells in BM (Spearman ρ = 0.550, P = 0.012;
Additional file 3: Figure S3D). For patients with metachro-
nous disease, there was no significant correlation between
PD-1+ TIL infiltration on brain TME and the interval of
development of BM. (Spearman ρ = 0.133, P = 0.744;
Additional file 4: Figure S4). Altogether, these results
revealed that the brain TME differed from that of the pri-
mary cancer in terms of an immunological environment,
with a markedly decreased amount of PD-1+ TILs. The
Fig. 1 Treatment response to anti–PD-1 antibody in cohort 1. (Upper) Pie charts demonstrating the response in primary lung cancer and paired
brain metastases. (Lower) The treatment response along with clinicodemographic characteristics of individual patients in cohort 1. Each patient
received either nivolumab (N) or pembrolizumab (P) for the specified number of cycles. Each tile in this figure denotes the treatment response:
red for progressive disease, blue for stable disease, and green for a partial response. Abbreviations: PD, progressive disease; PR, partial response;
SD, stable disease; ID, identification number; P, pembrolizumab; N, nivolumab; PD-L1, programmed cell death ligand-1; PD-1, programmed cell
death-1; M, male; F, female; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; NS, never smoked; ES, ex-smoker; CS,
current smoker; ADC, adenocarcinoma; SAR, pulmonary sarcomatoid carcinoma; SCL, small-cell lung cancer; SQC, squamous cell carcinoma,
Erlo., erlotinib; Gefi., gefitinib; ICI, immune checkpoint inhibitor; TKI, tyrosine kinase inhibitor. a: Exon 20 insertion. b: Exon 19 deletion.
c: L858R mutation
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infiltration of CD3+ and CD8+ TILs was also decreased, es-
pecially for lung adenocarcinoma.
Prognostic implication of immunological tumor
microenvironment in metastatic brain tumors
To investigate the prognostic significance of immuno-
logical TME of brain metastasis, the OS rate of cohort 2
after brain surgery was studied in terms of the amount
of CD3+ and PD1+ TILs, and PD-L1 expression on
tumor cells. Since there were no clear-cut off points for
these values, the median of each variable was arbitrarily
used as a cut-off point. All patients in cohort 2 did not
exhibit any survival differences (data not shown). For
adenocarcinoma patients in cohort 2, however, a higher
Fig. 2 Immunohistochemical analysis of CD3, CD4, CD8, FOXP3, and PD-1 on tumor-infiltrating lymphocytes, and PD-L1 on tumor cells of patients
in cohort 2. (Upper) Ladder plots demonstrate the different expression of each marker between primary lung cancer and brain metastases.
Individual patients in cohort 2 are denoted as different colored lines. Statistical significance was estimated using a paired Wilcoxon rank-sum test.
(Lower) Detailed information, including clinicodemographic characteristics, are summarized in this figure. Because lung biopsy tissues from 8
patients (patients 1, 5, 9, 11, 13, 14, 19, 20) were too small to be examined by IHC, paired analysis was possible in only 12 out of 20 patients in
cohort 2. Each colored tile in this figure represents the increased expression of each marker in the brain relative to that in primary lung cancers.
Abbreviations: PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; ID, identification number; EGFR, epidermal growth factor
receptor; ALK, anaplastic lymphoma kinase; Erlo., erlotinib; Gefi., gefitinib; TKI, tyrosine kinase inhibitor; ADC, adenocarcinoma; SQC, squamous cell
carcinoma; SAR, pulmonary sarcomatoid carcinoma; N, never smoked; C, current smoker; E, ex-smoker; M, metachronous; S, synchronous. a: Exon
19 deletion. b: L858R mutation
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infiltration of CD3+ TILs tended was associated with a
worse prognosis (HR 2.47, 95% CI 0.77–7.96; P = 0.130,
log-rank P = 0.119; Fig. 4a) Interestingly, patients show-
ing a higher infiltration of PD1+ TILs exhibited a dismal
prognosis that was statistically significant (HR, 1.20, 95%
CI, 1.01–11.04; P = 0.049; log-rank P = 0.039; Fig. 4b). In
terms of PD-L1 expression on tumor cells, there was no
prognostic implication according to the PD-L1 H-score
(HR 1.24, 95% CI 0.39–3.91; P = 0.711, log-rank P =
0.710; Fig. 4c). Collectively, this analysis showed that the
immunological TME in the brain had a prognostic im-
plication after brain metastasectomy, especially for pa-
tients with adenocarcinoma histology.
Discussion
In this study, we found that the BM of lung cancer did
not respond well to ICIs. Immunohistochemical analysis
revealed a decreased infiltration of PD-1+ TILs in BM
compared to primary lung cancer. These findings
demonstrate that decreased PD-1+ of TILs could be one
of the potential causative reasons for a poor intracranial
response to ICIs.
Activated T cells have the potential to penetrate the
blood–brain barrier (BBB) and readily infiltrate tumors
within the brain, giving rise to the possibility that an ICI
may have a therapeutic effect on BM [26]. However, the
brain has been generally considered an immune privi-
leged site that may dampen the therapeutic efficacy of
ICIs because of the presence of BBB [27]. Although
there has been no published pharmacokinetic or
pharmacodynamics studies in on-treatment brain tissue
to allow determination of drug penetration into the
tumor, some preclinical data demonstrated ICI’s
penetration to BBB for primary brain tumors and for
metastatic tumors. [28] Furthermore, for melanoma
patients with stable asymptomatic brain metastases,
ipilimumab, and to a lesser extent pembrolizumab,
did show any activity, with half of all patients achiev-
ing a partial response or stable disease [29]. Whether
this also applies to lung cancer patients is currently
being investigated in a number of early phase im-
munotherapy trials.
An recent interim analysis of a phase II study showed
that pembrolizumab may have a role in NSCLC patients
with brain metastases [19]. Unfortunately, however,
many patients did not respond to pembrolizumab in the
brain or in extracranial sites. Similarly, only 16.7% of the
patients in cohort 1 of the present study responded to
treatment for BM with anti–PD-1 antibody. Although
two patients achieved a partial response, they underwent
WBRT with anti–PD-1 antibody, making it difficult to
interpret the ICI response. The superior response rate
observed in the phase II study might be due to exclusion
of patients with any history of BM or active/symptom-
atic BM. In general, there is huge gap between clinical
trials and real world lung cancer patients because of
strict criteria for patient enrollment of clinical trials. [30]
Our study represents that the BM of lung cancer patient
in real world do not seem to respond well to ICIs.
Over the past decades, the TME has been considered a
fundamental regulator of cancer progression and thera-
peutic efficacy. The TME contains various noncancerous
cell types, including endothelial cells, pericytes, fibro-
blasts, and immune cells [21]. While several of these cell
types are common to both, there are significant differ-




















Fig. 3 Representative immunohistochemical images of PD-1, PD-L1, and CD8 in primary lung cancer and brain metastatic tissues of a patient
from cohort 2 (patient ID 17). Abbreviations: PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1
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brain, allowing mechanisms that regulate tumor cell
niches in the brain to differ from those of other tissues
[22, 23]. In order to explain why BM were not respon-
sive to ICIs, attention was paid to the immunological en-
vironment in the TME of the brain. The brain TME was
found to have lost PD-1+ TILs despite their presence in
primary lung cancer specimens, which is a novel finding
of this study. In accordance with others [31–33], adeno-
carcinoma patients displayed a more distinctive pattern
of a low infiltration of both CD3+ and CD8+ TILs, sug-
gesting that a significant number of patients lack any
significant local immune response in association with
their BM. Although PD-L1 expression of tumor cells
showed no significant differences in this study, others
have reported that BM lost PD-L1 expression that was
normally present in primary lung cancer specimens [22,
34]. Overall, such an immunological heterogeneity may
explain, at least in part, the different therapeutic re-
sponses to PD-1 inhibitors.
While limited data suggest that the intracranial re-
sponse to ICIs may have the distinct advantage of pro-
ducing durable responses in selected patients [19], there
is no definitive biomarker to identify this population. Al-
though there have been significant efforts to develop
PD-L1 as a predictive biomarker to select patients for
treatment with PD-1 or PD-L1 inhibitors, consensus cri-
teria for evaluating PD-L1 as a predictive biomarker
have not yet been settled [35]. As indicated in our study,
the immunological TME in the brain, including the infil-
tration of PD-1+ TILs, may be important in predicting
the clinical benefits of PD-1/PD-L1 checkpoint block-
ades in lung cancer patients with BM. Therefore, we
suggest that the role of PD-1 as a biomarker in the brain
TME should be investigated in future clinical studies of
immunotherapy in lung cancer with BM. When physi-
cians decide to treat patients with a PD-1 or PD-L1 in-
hibitor, the distinctive immunological environment of
the brain should be taken into consideration.
This study has several limitations. The two cohorts
analyzed in this study were small due to the limited
number of patients with BM who underwent anti–PD-1
antibody treatment or a brain metastasectomy. Further-
more, since the two cohorts were independent of each
other, the predictive role of PD-1 for anti–PD-1 anti-
body treatment could not be evaluated directly. How-
ever, it was sufficient to generate the hypothesis that
PD-1 could be a potential biomarker. Actually, some of
the progressive diseases observed in cohort 1 could
have been pseudoprogressions. However, the main pur-
pose of this study was to investigate the difference in
treatment response between BM and primary lung can-
cer, rather than the absolute response of each organ.
Therefore, the existence of pseudoprogression is un-
likely to change the conclusion of this study.
PD-1+ TIL < 3.58
PD-1+ TIL  3.58
PD-L1 H-score < 1.00








































CD3+ TIL < 247.20
CD3+ TIL  247.20
Fig. 4 Kaplan–Meier plots for lung cancer patients with
adenocarcinoma histology in cohort 2 according to a the amount of
CD3+ TILs, b PD1+ TILs, and c the PD-L1 H-score in brain metastatic
tissue. Overall survival was measured from the date of surgery until
either death due to any cause or the last follow-up date. The cutoff-
points were arbitrarily set to the median value of each variable. The
significance of differences in survival curves were compared using a
log-rank test. Abbreviations: TIL, tumor-infiltrating lymphocyte; PD-1,
programmed cell death-1; PD-L1, programmed cell death ligand-1
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Conclusions
Our findings suggest that there may be discordant extra/
intracranial responses to ICIs. The diminished infiltra-
tion of PD-1+ TILs into tumor tissue in the brain may
be one of potential factors that hinders the response to
anti-PD-1 antibody in the BM. These findings provide a
rationale for studying the infiltration of PD-1+ TILs in
the brain as a potential biomarker for future immuno-
therapy trials that incorporate patients with BM. Hope-
fully, ongoing studies will improve treatment selection
strategies for lung cancer patients with BM.
Additional files
Additional file 1: Figure S1. Representative images for response
evaluation in brain metastasis. An intracranial response was assessed
by brain gadolinium-enhanced magnetic resonance imaging, using
Response Evaluation Criteria in Solid Tumors modified to allow target
central nerve system lesions, 5 mm or larger in maximum diameter,
and with up to five BMs permitted (modified RECIST). Each patient
received either nivolumab (N) or pembrolizumab (P) for the specified
number of cycles. Abbreviations: ADC, adenocarcinoma; SCL, small-
cell lung cancer; SAR, pulmonary sarcomatoid carcinoma; P, pembroli-
zumab; N, nivolumab; PD, progressive disease; PR, partial response;
SD, stable disease. (TIF 2970 kb)
Additional file 2: Figure S2. Immunohistochemical analysis of CD3,
CD4, CD8, FOXP3, and PD-1 on tumor-infiltrating lymphocytes, and
PD-L1 on tumor cells of patients with an adenocarcinoma histology
in cohort 2. Ladder plots demonstrate the different expression of
each marker between primary lung cancer and brain metastases.
Individual patients are denoted as different colored lines. Statistical
significance was estimated using a paired Wilcoxon rank sum test.
(TIF 497 kb)
Additional file 3: Figure S3. Scatter plots demonstrating the
correlation between PD-L1 expression on tumor cells and the
amount of CD3+ TILs or PD1+ TILs in primary lung cancer specimens,
and metastatic brain tumors. Correlation was evaluated by Spear-
man’s rank correlation analysis. Abbreviations: PD-L1, programmed
cell death ligand-1; TIL, tumor-infiltrating lymphocyte. (TIF 379 kb)
Additional file 4: Figure S4. Scatter plot demonstrating the correlation
between infiltrating PD-1+ tumor-infiltrating lymphocyte on brain metas-
tasis and the interval of development of brain metastasis. Correlation was
evaluated by Spearman’s rank correlation analysis. Abbreviations: PD-1,
programmed cell death-1; TIL, tumor-infiltrating lymphocyte. (TIF 143 kb)
Abbreviations
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PD-L1: Programmed cell death ligand-1; PR: Partial response; SAR: Pulmonary
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